EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI) company president Brandon Keks reports that three shipping containers of production equipment and supplies are currently en route to port in Ghana. All technical production and administrative employees have been interviewed and employment agreements are being reviewed and signed. We have in place an experienced and excited team ready to go to work.

Raw materials are being shipped by air and we are on schedule to begin test runs for the production of several generic pharmaceuticals by the end of May. African Global Pharma will then proceed to produce a variety of generic medicines. There are thirteen different medicines slated to begin production with a further eighteen to be registered as production capacity is expanded.

Emerging World Pharma president Brandon Keks is currently in Africa and will continue to oversee and report on the continued progress in the Sunyani, Ghana manufacturing facilities. www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com